Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 201...
February 08 2016 - 4:35PM
Business Wire
Novocure’s (NASDAQ: NVCR) phase 3 pivotal clinical trial results
of Tumor Treating Fields (TTFields) in combination with
temozolomide in newly diagnosed glioblastoma (GBM) have been
selected for inclusion in the American Society of Clinical
Oncology’s Clinical Cancer Advances 2016: Annual Report on Progress
Against Cancer. The report, which was published first online on
Feb. 4 in the Journal of Clinical Oncology, reviews the recent top
advances and emerging trends in clinical cancer research that are
leading to improved cancer treatments for patients.
“Clinical Cancer Advances 2016 represents and acknowledges the
collective wisdom that has made progress against cancer possible,”
ASCO President Julie M. Vose wrote in the report. “I hope these
achievements will inspire all of us to do our part to further
accelerate the pace of research and discovery to help millions of
people who are living with cancer and the millions more who will
face a cancer diagnosis in their lifetime.”
Novocure’s phase 3 pivotal trial compared TTFields therapy in
combination with temozolomide to temozolomide alone in 695 patients
with newly diagnosed GBM. The trial met its endpoints at the
interim analysis. The trial’s results demonstrated superior
progression-free and overall survivals in patients receiving
TTFields therapy in combination with temozolomide compared to
temozolomide alone (median progression-free survival of 7.2 months
compared to 4.0 months, hazard ratio=0.62, p=0.001; median overall
survival of 20.5 months compared to 15.6 months, hazard ratio=0.66,
p=0.004).
In October 2015, the U.S. Food and Drug Administration approved
Optune – a portable, non-invasive device that delivers TTFields –
in combination with temozolomide for the treatment of adult
patients with newly diagnosed glioblastoma. TTFields are the first
FDA-approved therapy in more than a decade to demonstrate
statistically significant extension of overall survival in newly
diagnosed GBM, with a two-year survival of 48 percent versus 32
percent compared to temozolomide alone.
“We are honored that our research has been selected as a top
advancement in cancer care by ASCO, a leading organization in
oncology research and education,” said Novocure CEO Asaf Danziger.
“Such advancements are critical to improving treatment and
extending the lives of cancer patients. We are proud to receive
this designation and believe it will help raise awareness of the
benefits of TTFields therapy within the broader oncology
community.”
About Novocure
Novocure is a Jersey Isle oncology company pioneering a novel
therapy for solid tumors called TTFields. Novocure’s U.S.
operations are based in Portsmouth, New Hampshire, and New York
City. Additionally, the company has offices in Germany,
Switzerland, and Japan and a research center in Haifa, Israel. For
additional information about the company, please visit
www.novocure.com or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe" or other words and terms of similar meaning.
Novocure's performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Quarterly Report on Form
10-Q filed on Oct. 27, 2015, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160208006287/en/
Media and Investor Contact:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024